(76) also reported a case of lung adenocarcinoma with EML4-ALK fusion after sequential treatment with alectinib and brigatinib, where MET gene exon 14 skipping mutation was detected only in the patient’s plasma cell-free DNA. The gene discussed is MET; the disease is lung adenocarcinoma.